{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:05:32Z","timestamp":1784210732896,"version":"3.55.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12287-8","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:17:44Z","timestamp":1784207864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Agomelatine versus gefitinib against HepG2 cells: Modulating PI3K\/AKT and MAPK\/RAF1\/c-FOS pathways"],"prefix":"10.1007","volume":"53","author":[{"given":"Heba M.","family":"Abd El Kareem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara F.","family":"Saadawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai M.","family":"ELdaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Al-Saraireh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba A.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"12287_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3350\/cmh.2023.0070","volume":"29","author":"JH Oh","year":"2023","unstructured":"Oh JH, Jun DW (2023) The latest global burden of liver cancer: A past and present threat. Clin Mol Hepatol 29:355\u2013357. https:\/\/doi.org\/10.3350\/cmh.2023.0070","journal-title":"Clin Mol Hepatol"},{"key":"12287_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/MEG.0000000000002057","volume":"33","author":"LRC Saud","year":"2021","unstructured":"Saud LRC, Chagas AL, Maccali C, Pinto PVA, Horvat N, Alencar RSSM, Tani CM, Abdala E, Carrilho FJ (2021) Hepatocellular carcinoma in patients coinfected with hepatitis B or C and HIV: more aggressive tumor behavior? Eur J Gastroenterol Hepatol 33:583\u2013588. https:\/\/doi.org\/10.1097\/MEG.0000000000002057","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"12287_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3390\/biomedicines9101345","volume":"9","author":"L Rinaldi","year":"2021","unstructured":"Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC (2021) HCC and molecular targeting therapies: Back to the future. Biomedicines 9(10):1345. https:\/\/doi.org\/10.3390\/biomedicines9101345","journal-title":"Biomedicines"},{"key":"12287_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.12688\/f1000research.145493.2","volume":"13","author":"TK-H Wu","year":"2024","unstructured":"Wu TKH, Hui RWH, Mak LY, Fung J, Seto WK, Yuen MF (2024) Hepatocellular carcinoma: Advances in systemic therapies. F1000Research 13:104. https:\/\/doi.org\/10.12688\/f1000research.145493.2","journal-title":"F1000Research"},{"key":"12287_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, De Toni EN, Wang X (2020) The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 5:87. https:\/\/doi.org\/10.1038\/s41392-020-0187-x","journal-title":"Signal Transduct Target Ther"},{"key":"12287_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK, Dewanjee S, Vallamkondu J (2023) P\u00e9rez de la Lastra, Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 10:1367\u20131401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007","journal-title":"Genes Dis"},{"issue":"4","key":"12287_CR7","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/biomedicines11041166","volume":"11","author":"E Kouroumalis","year":"2023","unstructured":"Kouroumalis E, Tsomidis I, Voumvouraki A (2023) Pathogenesis of hepatocellular carcinoma: The interplay of apoptosis and autophagy. Biomedicines 11(4):1166. https:\/\/doi.org\/10.3390\/biomedicines11041166","journal-title":"Biomedicines"},{"key":"12287_CR8","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1007\/s12035-023-03433-5","volume":"60","author":"G Sahoo","year":"2023","unstructured":"Sahoo G, Samal D, Khandayataray P, Murthy MK (2023) A review on caspases: Key regulators of biological activities and apoptosis. Mol Neurobiol 60:5805\u20135837. https:\/\/doi.org\/10.1007\/s12035-023-03433-5","journal-title":"Mol Neurobiol"},{"key":"12287_CR9","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3389\/fonc.2019.01421","volume":"9","author":"JU Marquardt","year":"2019","unstructured":"Marquardt JU, Edlich F (2019) Predisposition to apoptosis in hepatocellular carcinoma: From mechanistic insights to therapeutic strategies. Front Oncol 9:1421. https:\/\/doi.org\/10.3389\/fonc.2019.01421","journal-title":"Front Oncol"},{"issue":"3","key":"12287_CR10","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.3390\/ijms24032652","volume":"24","author":"LY Tian","year":"2023","unstructured":"Tian LY, Smit DJ, J\u00fccker M (2023) The role of PI3K\/AKT\/mTOR signaling in hepatocellular carcinoma metabolism. Int J Mol Sci 24(3):2652. https:\/\/doi.org\/10.3390\/ijms24032652","journal-title":"Int J Mol Sci"},{"key":"12287_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-020-01629-4","volume":"39","author":"J Feng","year":"2020","unstructured":"Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, Dai W, Guo C (2020) Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res 39:126. https:\/\/doi.org\/10.1186\/s13046-020-01629-4","journal-title":"J Exp Clin Cancer Res"},{"key":"12287_CR12","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.7150\/ijbs.89942","volume":"20","author":"F Fontana","year":"2024","unstructured":"Fontana F, Giannitti G, Marchesi S, Limonta P (2024) The PI3K\/Akt pathway and glucose metabolism: A dangerous liaison in cancer. Int J Biol Sci 20:3113\u20133125. https:\/\/doi.org\/10.7150\/ijbs.89942","journal-title":"Int J Biol Sci"},{"key":"12287_CR13","doi-asserted-by":"publisher","first-page":"854","DOI":"10.17179\/excli2025-8479","volume":"24","author":"J Fei","year":"2025","unstructured":"Fei J, Guo Y (2025) Signaling in Tumorigenesis: mechanisms of growth, invasion, and angiogenesis. EXCLI J 24:854\u2013879. https:\/\/doi.org\/10.17179\/excli2025-8479","journal-title":"EXCLI J"},{"key":"12287_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.2174\/1574892818666221026164940","volume":"18","author":"P Kumar","year":"2023","unstructured":"Kumar P, Mangla B, Javed S, Ahsan W, Musyuni P, Ahsan A, Aggarwal G (2023) Gefitinib: An updated review of its role in the cancer management, its nanotechnological interventions, recent patents and clinical trials, recent pat. Anticancer Drug Discov 18:448\u2013469. https:\/\/doi.org\/10.2174\/1574892818666221026164940","journal-title":"Anticancer Drug Discov"},{"key":"12287_CR15","doi-asserted-by":"publisher","first-page":"110108","DOI":"10.1016\/j.cbi.2022.110108","volume":"366","author":"KS Alharbi","year":"2022","unstructured":"Alharbi KS, Javed Shaikh MA, Afzal O, Alfawaz Altamimi AS, Almalki WH, Alzarea SI, Kazmi I, Al-Abbasi FA, Singh SK, Dua K, Gupta G (2022) An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy. Chem Biol Interact 366:110108. https:\/\/doi.org\/10.1016\/j.cbi.2022.110108","journal-title":"Chem Biol Interact"},{"key":"12287_CR16","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1080\/10408398.2021.2000933","volume":"63","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Farooqi AA, Xu B (2023) Comprehensive review on signaling pathways of dietary saponins in cancer cells suppression. Crit Rev Food Sci Nutr 63:4325\u20134350. https:\/\/doi.org\/10.1080\/10408398.2021.2000933","journal-title":"Crit Rev Food Sci Nutr"},{"key":"12287_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2025.9035","volume":"55","author":"L Jin","year":"2026","unstructured":"Jin L, Wei L, Hua J, Zhang R, Chen J, He J, Yang Y (2026) Inhibition of primary ciliogenesis enhances efficacy of EGFR-TKIs against non-small cell lung cancer cells. Oncol Rep 55:1\u201312. https:\/\/doi.org\/10.3892\/or.2025.9035","journal-title":"Oncol Rep"},{"key":"12287_CR18","doi-asserted-by":"publisher","first-page":"102426","DOI":"10.1016\/j.mtbio.2025.102426","volume":"35","author":"G Li","year":"2025","unstructured":"Li G, Cai C, Zhang N, Wang Z, Zhang M, Liu Q, Chen S, Shang Y, Zhao C, Ren S, An H (2025) Carrier-free procyanidin-ferric nanonetworks loading gefitinib to inhibit TMEM16A-EGFR mutual activation loop for photothermally enhanced breast cancer targeted therapy. Mater Today Bio 35:102426. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102426","journal-title":"Mater Today Bio"},{"key":"12287_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20451253221105128","volume":"12","author":"MJ Millan","year":"2022","unstructured":"Millan MJ (2022) Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action. Ther Adv Psychopharmacol 12:1\u201319. https:\/\/doi.org\/10.1177\/20451253221105128","journal-title":"Ther Adv Psychopharmacol"},{"key":"12287_CR20","doi-asserted-by":"publisher","first-page":"1007006","DOI":"10.3389\/fphar.2022.1007006","volume":"13","author":"L Bai","year":"2022","unstructured":"Bai L, Sun S, Su W, Chen C, Lv Y, Zhang J, Zhao J, Li M, Qi Y, Zhang W, Wang Y (2022) Melatonin inhibits HCC progression through regulating the alternative splicing of NEMO. Front Pharmacol 13:1007006. https:\/\/doi.org\/10.3389\/fphar.2022.1007006","journal-title":"Front Pharmacol"},{"issue":"1","key":"12287_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/antiox10010103","volume":"10","author":"P Fernandez-Palanca","year":"2021","unstructured":"Fernandez-Palanca P, Mendez-Blanco C, Fondevila F, Tu\u00f1\u00f3n MJ, Reiter RJ, Mauriz JL, Gonzalez-Gallego J (2021) Melatonin as an antitumor agent against liver cancer: an updated systematic review. Antioxidants 10(1):103. https:\/\/doi.org\/10.3390\/antiox10010103","journal-title":"Antioxidants"},{"key":"12287_CR22","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00109-006-0097-6","volume":"84","author":"JH Schefe","year":"2006","unstructured":"Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H (2006) Quantitative real-time RT-PCR data analysis: Current concepts and the novel \u2018gene expression\u2019s C T difference\u2019 formula. J Mol Med 84:901\u2013910. https:\/\/doi.org\/10.1007\/s00109-006-0097-6","journal-title":"J Mol Med"},{"key":"12287_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12906-017-1594-6","volume":"17","author":"S Khazaei","year":"2017","unstructured":"Khazaei S, Abdul Hamid R, Mohd Esa N, Ramachandran V, Aalam GTF, Etemad A, Ismail P (2017) Promotion of HepG2 cell apoptosis by flower of Allium atroviolaceum and the mechanism of action. BMC Complement Altern Med 17:104. https:\/\/doi.org\/10.1186\/s12906-017-1594-6","journal-title":"BMC Complement Altern Med"},{"key":"12287_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/sca.21245","volume":"38","author":"J Pi","year":"2016","unstructured":"Pi J, Li B, Tu L, Zhu H, Jin H, Yang F, Bai H, Cai H, Cai J (2016) Investigation of quercetin-induced HepG2 cell apoptosis-associated cellular biophysical alterations by atomic force microscopy. Scanning 38:100\u2013112. https:\/\/doi.org\/10.1002\/sca.21245","journal-title":"Scanning"},{"issue":"7","key":"12287_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/diseases13070207","volume":"13","author":"N Amin","year":"2025","unstructured":"Amin N, Anwar J, Sulaiman A, Naumova NN, Anwar N (2025) Hepatocellular carcinoma: a comprehensive review. Diseases 13(7):207. https:\/\/doi.org\/10.3390\/diseases13070207","journal-title":"Diseases"},{"key":"12287_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.17998\/jlc.2023.08.27","volume":"23","author":"JH Yoon","year":"2023","unstructured":"Yoon JH, Choi SK (2023) Management of early-stage hepatocellular carcinoma: challenges and strategies for optimal outcomes. J Liver Cancer 23:300\u2013315. https:\/\/doi.org\/10.17998\/jlc.2023.08.27","journal-title":"J Liver Cancer"},{"key":"12287_CR27","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1016\/j.cell.2026.03.001","volume":"189","author":"JM Llovet","year":"2026","unstructured":"Llovet JM, Pinyol R, Affo S, Yarchoan M, Gores GJ, Kelley RK, Lowe SW, Sia D, Villanueva A (2026) Hallmarks of liver cancer: Therapeutic implications. Cell 189:2490\u20132514. https:\/\/doi.org\/10.1016\/j.cell.2026.03.001","journal-title":"Cell"},{"key":"12287_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41422-025-01126-3","volume":"35","author":"T Hou","year":"2025","unstructured":"Hou T, Yan P, Inuzuka H, Wei W (2025) Lysosomal EGFR functions as a GEF for Rheb. Cell Res 35:475\u2013476. https:\/\/doi.org\/10.1038\/s41422-025-01126-3","journal-title":"Cell Res"},{"issue":"8","key":"12287_CR29","doi-asserted-by":"publisher","first-page":"e191735","DOI":"10.1172\/JCI191735","volume":"136","author":"Y Zhao","year":"2026","unstructured":"Zhao Y, Zhou Y, Pan L, Tian GG, Huang H-Y, Tang S, Lu M, Zhou Z, Zhang P, Chen L, Zhang L, Hu L (2026) Ji H Therapy-induced cholesterol biosynthesis drives lung cancer dormancy and drug resistance. J Clin Investig 136(8):e191735. https:\/\/doi.org\/10.1172\/JCI191735","journal-title":"J Clin Investig"},{"issue":"18","key":"12287_CR30","doi-asserted-by":"publisher","first-page":"10008","DOI":"10.3390\/ijms251810008","volume":"25","author":"H Dickerson","year":"2024","unstructured":"Dickerson H, Diab A, Al Musaimi O (2024) Epidermal growth factor receptor tyrosine kinase inhibitors in cancer: Current use and future prospects. Int J Mol Sci 25(18):10008. https:\/\/doi.org\/10.3390\/ijms251810008","journal-title":"Int J Mol Sci"},{"key":"12287_CR31","doi-asserted-by":"publisher","first-page":"1516583","DOI":"10.3389\/fphar.2025.1516583","volume":"16","author":"M Qiang","year":"2025","unstructured":"Qiang M, Chen Z, Liu H, Dong J, Gong K, Zhang X, Huo P, Zhu J, Shao Y, Ma J, Zhang B (2025) Targeting the PI3K\/AKT\/mTOR pathway in lung cancer: mechanisms and therapeutic targeting. Front Pharmacol 16:1516583. https:\/\/doi.org\/10.3389\/fphar.2025.1516583","journal-title":"Front Pharmacol"},{"issue":"13","key":"12287_CR32","doi-asserted-by":"publisher","first-page":"10944","DOI":"10.3390\/ijms241310944","volume":"24","author":"J Zhang","year":"2023","unstructured":"Zhang J, Xiang Q, Wu M, Lao YZ, Xian YF, Xu HX, Lin ZX (2023) Autophagy regulators in cancer. Int J Mol Sci 24(13):10944. https:\/\/doi.org\/10.3390\/ijms241310944","journal-title":"Int J Mol Sci"},{"key":"12287_CR33","doi-asserted-by":"publisher","first-page":"10163","DOI":"10.1007\/s00210-026-04999-2","volume":"399","author":"A Singh","year":"2026","unstructured":"Singh A, Kumar V, Prachi K, Rajan N, Singh S, Rajamanickam VM (2026) Preclinical evaluation of gefitinib and betulin-loaded surface functionalized liposomes for the treatment of hepatocellular carcinoma via asialoglycoprotein receptor targeting, Naunyn. Schmiedebergs Arch Pharmacol 399:10163\u201310184. https:\/\/doi.org\/10.1007\/s00210-026-04999-2","journal-title":"Schmiedebergs Arch Pharmacol"},{"key":"12287_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jhep.2012.02.019","volume":"57","author":"M-J Blivet-Van","year":"2012","unstructured":"Blivet-Van M-J, Eggelpo\u00ebl H, Chettouh L, Fartoux L, Aoudjehane V, Barbu C, Rey S, Priam C, Housset O, Rosmorduc C, Desbois-Mouthon (2012) Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 57:108\u2013115. https:\/\/doi.org\/10.1016\/j.jhep.2012.02.019","journal-title":"J Hepatol"},{"key":"12287_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3350\/cmh.2015.21.1.49","volume":"21","author":"HR Gu","year":"2015","unstructured":"Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, No SH, Jeong J-H (2015) Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells. Clin Mol Hepatol 21:49\u201359. https:\/\/doi.org\/10.3350\/cmh.2015.21.1.49","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"12287_CR36","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.3390\/cancers14122928","volume":"14","author":"Q Wang","year":"2022","unstructured":"Wang Q, Shen X, Chen G, Du J (2022) Drug resistance in colorectal cancer: from mechanism to clinic. Cancers 14(12):2928. https:\/\/doi.org\/10.3390\/cancers14122928","journal-title":"Cancers"},{"issue":"8","key":"12287_CR37","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.3390\/pharmaceutics15082130","volume":"15","author":"J Bang","year":"2023","unstructured":"Bang J, Jun M, Lee S, Moon H, Ro SW (2023) Targeting EGFR\/PI3K\/AKT\/mTOR signaling in hepatocellular carcinoma. Pharmaceutics 15(8):2130. https:\/\/doi.org\/10.3390\/pharmaceutics15082130","journal-title":"Pharmaceutics"},{"key":"12287_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","volume":"3","author":"Q Li","year":"2022","unstructured":"Li Q, Li Z, Luo T, Shi H (2022) Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy. Mol Biomed 3:47. https:\/\/doi.org\/10.1186\/s43556-022-00110-2","journal-title":"Mol Biomed"},{"issue":"12","key":"12287_CR39","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.3390\/cancers13123026","volume":"13","author":"H Moon","year":"2021","unstructured":"Moon H, Ro SW (2021) MAPK\/ERK signaling pathway in hepatocellular carcinoma. Cancers 13(12):3026. https:\/\/doi.org\/10.3390\/cancers13123026","journal-title":"Cancers"},{"key":"12287_CR40","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3109\/15622975.2011.595823","volume":"12","author":"G Racagni","year":"2011","unstructured":"Racagni G, Riva MA, Molteni R, Musazzi L, Calabrese F, Popoli M, Tardito D (2011) Mode of action of agomelatine: Synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry 12:574\u2013587. https:\/\/doi.org\/10.3109\/15622975.2011.595823","journal-title":"World J Biol Psychiatry"},{"issue":"4","key":"12287_CR41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/ijms18040843","volume":"18","author":"RJ Reiter","year":"2017","unstructured":"Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, Xu K (2017) Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis. Int J Mol Sci 18(4):843. https:\/\/doi.org\/10.3390\/ijms18040843","journal-title":"Int J Mol Sci"},{"key":"12287_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.32604\/or.2026.077020","volume":"34","author":"J Nuszkiewicz","year":"2026","unstructured":"Nuszkiewicz J, Wr\u00f3blewska J, J\u00f3\u017awiak M, Paw\u0142owska M (2026) Melatonin in Integrative Oncology: Biological Mechanisms, Therapeutic Evidence and Implementation Strategies. Oncol Res 34:6. https:\/\/doi.org\/10.32604\/or.2026.077020","journal-title":"Oncol Res"},{"key":"12287_CR43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2147\/BCTT.S139963","volume":"9","author":"RE Kast","year":"2017","unstructured":"Kast RE, Skuli N, Cos S, Karpel-Massler G, Shiozawa Y, Goshen R, Halatsch M-E (2017) The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy. Breast Cancer (Dove Med Press 9:495\u2013514. https:\/\/doi.org\/10.2147\/BCTT.S139963","journal-title":"Breast Cancer (Dove Med Press"},{"issue":"12","key":"12287_CR44","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.3390\/ijms26125703","volume":"26","author":"SK Jang","year":"2025","unstructured":"Jang SK, Choi J, Lim HW, Kim HG, Yoo YM (2025) Comparative analysis of melatonin and polydeoxyribonucleotide: Possible benefits of co-treatment effects and potential synergistic applicability. Int J Mol Sci 26(12):5703. https:\/\/doi.org\/10.3390\/ijms26125703","journal-title":"Int J Mol Sci"},{"issue":"1","key":"12287_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.32794\/mr11250087","volume":"4","author":"AO de Carnevale Galeti","year":"2021","unstructured":"de Carnevale Galeti AO, de Oliveira JG, Pinheiro MG, dos Santos MB, Colombo J, de Almeida Chuffa LG, de Campos Zuccari DA (2021) Verification of agomelatine in comparison with melatonin as a therapeutic agent to treat breast cancer. Melatonin Res 4(1):141\u2013151. https:\/\/api.semanticscholar.org\/CorpusID:233254696","journal-title":"Melatonin Res"},{"key":"12287_CR46","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1080\/21655979.2021.2023803","volume":"13","author":"H Liu","year":"2022","unstructured":"Liu H, Wang F, Zhao J, Zhang X, Zeng Z, Wang S, Guan J, Qin H (2022) The effect and mechanisms of melatonin on the proliferation and apoptosis of lung cancer cells. Bioengineered 13:3462\u20133469. https:\/\/doi.org\/10.1080\/21655979.2021.2023803","journal-title":"Bioengineered"},{"key":"12287_CR47","doi-asserted-by":"publisher","first-page":"1617508","DOI":"10.3389\/fphar.2025.1617508","volume":"16","author":"Y Cao","year":"2025","unstructured":"Cao Y, Zhang H, Chen X, Li C, Chen J (2025) Melatonin: a natural guardian in cancer treatment. Front Pharmacol 16:1617508. https:\/\/doi.org\/10.3389\/fphar.2025.1617508","journal-title":"Front Pharmacol"},{"key":"12287_CR48","doi-asserted-by":"publisher","first-page":"176292","DOI":"10.1016\/j.ejphar.2023.176292","volume":"963","author":"Z Wang","year":"2024","unstructured":"Wang Z, Lin D, Cui B, Zhang D, Wu J, Ma J (2024) Melatonin protects against myocardial ischemia-reperfusion injury by inhibiting excessive mitophagy through the Apelin\/SIRT3 signaling axis. Eur J Pharmacol 963:176292. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176292","journal-title":"Eur J Pharmacol"},{"key":"12287_CR49","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12935-022-02825-2","volume":"22","author":"A Mihanfar","year":"2022","unstructured":"Mihanfar A, Yousefi B, Azizzadeh B, Majidinia M (2022) Interactions of melatonin with various signaling pathways: implications for cancer therapy. Cancer Cell Int 22:420. https:\/\/doi.org\/10.1186\/s12935-022-02825-2","journal-title":"Cancer Cell Int"},{"issue":"7","key":"12287_CR50","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.3390\/ijms23073779","volume":"23","author":"L Wang","year":"2022","unstructured":"Wang L, Wang C, Choi WS (2022) Use of melatonin in cancer treatment: where are we? Int J Mol Sci 23(7):3779. https:\/\/doi.org\/10.3390\/ijms23073779","journal-title":"Int J Mol Sci"},{"key":"12287_CR51","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/fcp.12813","volume":"36","author":"G\u00d6 \u00d6nder","year":"2022","unstructured":"\u00d6nder G\u00d6, Sezer G, \u00d6zdamar S, Yay A (2022) Melatonin has an inhibitory effect on MCF-7 and MDA-MB-231 human breast cancer cell lines by inducing autophagy and apoptosis. Fundam \\& Clin Pharmacol 36:1038\u20131056. https:\/\/doi.org\/10.1111\/fcp.12813","journal-title":"Fundam \\& Clin Pharmacol"},{"key":"12287_CR52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1600-079X.2007.00548.x","volume":"45","author":"JG Pizarro","year":"2008","unstructured":"Pizarro JG, Yeste-Velasco M, Esparza JL, Verdaguer E, Pall\u00e0s M, Camins A, Folch J (2008) The antiproliferative activity of melatonin in B65 rat dopaminergic neuroblastoma cells is related to the downregulation of cell cycle-related genes. J Pineal Res 45:8\u201316. https:\/\/doi.org\/10.1111\/j.1600-079X.2007.00548.x","journal-title":"J Pineal Res"},{"key":"12287_CR53","doi-asserted-by":"publisher","first-page":"e70101","DOI":"10.1111\/jpi.70101","volume":"78","author":"M Gonciarz","year":"2026","unstructured":"Gonciarz M, Wiatrak B, Lombard I, Konecki \u0141, Sarbinowska J (2026) Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications. J Pineal Res 78:e70101. https:\/\/doi.org\/10.1111\/jpi.70101","journal-title":"J Pineal Res"},{"key":"12287_CR54","doi-asserted-by":"publisher","unstructured":"Bilgic Y, Akbulut S, Yildirim O, Ozhan O, Yildiz A, Erdemli Z, Erdemli ME, Kose A, Vardi N, Turkoz Y, Parlakpinar H (2026) Cytoprotective effects of agomelatine on hepatic ischemia\u2013reperfusion injury in a rat model. Int J Mol Sci 27. https:\/\/doi.org\/10.3390\/ijms27073246","DOI":"10.3390\/ijms27073246"},{"issue":"8","key":"12287_CR55","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/antiox11081621","volume":"11","author":"J Florido","year":"2022","unstructured":"Florido J, Rodriguez-Santana C, Martinez-Ruiz L, L\u00f3pez-Rodr\u00edguez A, Acu\u00f1a-Castroviejo D, Rusanova I, Escames G (2022) Understanding the mechanism of action of melatonin, which induces ROS production in cancer cells. Antioxidants 11(8):1621. https:\/\/doi.org\/10.3390\/antiox11081621","journal-title":"Antioxidants"},{"key":"12287_CR56","doi-asserted-by":"publisher","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","volume":"12","author":"Y Peng","year":"2022","unstructured":"Peng Y, Wang Y, Zhou C, Mei W, Zeng C (2022) PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: Are we making headway? Front Oncol Volume 12:819128. https:\/\/doi.org\/10.3389\/fonc.2022.819128","journal-title":"Front Oncol Volume"},{"issue":"158","key":"12287_CR57","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1101\/gad.191101","volume":"15","author":"A Schulze","year":"2001","unstructured":"Schulze A, Lehmann K, Jefferies HB, McMahon M, Downward J (2001) Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev 15;15(8):981\u2013994. https:\/\/genesdev.cshlp.org\/content\/15\/8\/981","journal-title":"Genes Dev"},{"key":"12287_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/oxfordjournals.jbchem.a002947","volume":"130","author":"A Matsuzawa","year":"2001","unstructured":"Matsuzawa A, Ichijo H (2001) Molecular Mechanisms of the Decision between Life and Death: Regulation of Apoptosis by Apoptosis Signal-Regulating Kinase 1. J Biochem 130:1\u20138. https:\/\/doi.org\/10.1093\/oxfordjournals.jbchem.a002947","journal-title":"J Biochem"},{"key":"12287_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.1007006","volume":"13","author":"L Bai","year":"2022","unstructured":"Bai L, Sun S, Su W, Chen C, Lv Y, Zhang J, Zhao J, Li M, Qi Y, Zhang W, Wang Y (2022) Melatonin inhibits HCC progression through regulating the alternative splicing of NEMO. Front Pharmacol 13:1\u201313. https:\/\/doi.org\/10.3389\/fphar.2022.1007006","journal-title":"Front Pharmacol"},{"key":"12287_CR60","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.molmed.2017.10.004","volume":"23","author":"G Maubach","year":"2017","unstructured":"Maubach G, Schm\u00e4dicke A-C, Naumann M (2017) NEMO Links Nuclear Factor-\u03baB to Human Diseases. Trends Mol Med 23:1138\u20131155. https:\/\/doi.org\/10.1016\/j.molmed.2017.10.004","journal-title":"Trends Mol Med"},{"issue":"15","key":"12287_CR61","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/cells14151207","volume":"14","author":"M Nigam","year":"2025","unstructured":"Nigam M, Punia B, Dimri DB, Mishra AP, Radu AF, Bungau G (2025) Reactive oxygen species: A double-edged sword in the modulation of cancer signaling pathway dynamics. Cells 14(15):1207. https:\/\/doi.org\/10.3390\/cells14151207","journal-title":"Cells"},{"issue":"4","key":"12287_CR62","doi-asserted-by":"publisher","first-page":"e70062","DOI":"10.1111\/jpi.70062","volume":"77","author":"KH Lu","year":"2025","unstructured":"Lu KH, Hsieh YH, Lin RC, Tsai MY, Yang SF (2025) Melatonin: a potential therapy for osteoporosis with insights into molecular mechanisms. J Pineal Res 77(4):e70062. https:\/\/doi.org\/10.1111\/jpi.70062","journal-title":"J Pineal Res"},{"issue":"1","key":"12287_CR63","doi-asserted-by":"publisher","first-page":"e220075","DOI":"10.1530\/JME-22-0075","volume":"70","author":"L Xu","year":"2023","unstructured":"Xu L, Li H, Zhang O, Zhang F, Song M, Ma M, Zhao Y, Ding R, Li D, Dong Z, Jin S (2023) Melatonin alleviates diet-induced steatohepatitis by targeting multiple cell types in the liver to suppress inflammation and fibrosis. J Mol Endocrinol 70(1):e220075. https:\/\/doi.org\/10.1530\/JME-22-0075","journal-title":"J Mol Endocrinol"},{"issue":"5","key":"12287_CR64","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3390\/brainsci13050734","volume":"13","author":"R Di Savino","year":"2023","unstructured":"Savino R, Polito AN, Marsala G, Ventriglio A, Di Salvatore M, De Stefano MI, Valenzano A, Marinaccio L, Bellomo A, Cibelli G, Monda M (2023) Agomelatine: a potential multitarget compound for neurodevelopmental disorders. Brain Sci 13(5):734. https:\/\/doi.org\/10.3390\/brainsci13050734","journal-title":"Brain Sci"},{"key":"12287_CR65","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1186\/s12967-025-07283-8","volume":"23","author":"L Li","year":"2025","unstructured":"Li L, Zhang H, Li W, Yuan Z, Zhao W, Luo Z (2025) Neuroglobin-promoted autophagy inhibits the proliferation, migration and invasion of human glioblastoma cells through the EGFR\/PI3K\/AKT\/mTOR signaling pathway. J Transl Med 23:1248. https:\/\/doi.org\/10.1186\/s12967-025-07283-8","journal-title":"J Transl Med"},{"key":"12287_CR66","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41422-025-01110-x","volume":"35","author":"X He","year":"2025","unstructured":"He X, Wang Q-X, Wei D, Lin Y, Zhang X, Wu Y, Qian X, Lin Z, Xiao B, Wu Q, Wang Z, Zhou F, Wei Z, Wang J, Gong R, Zhang R, Zhang Q, Ding K, Gao S, Kang T (2025) Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1. Cell Res 35:497\u2013509. https:\/\/doi.org\/10.1038\/s41422-025-01110-x","journal-title":"Cell Res"},{"key":"12287_CR67","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1600-079X.2008.00641.x","volume":"45","author":"J Mart\u00edn-Renedo","year":"2008","unstructured":"Mart\u00edn-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andr\u00e9s O, Gonz\u00e1lez P, Gonz\u00e1lez-Gallego J (2008) Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res 45:532\u2013540. https:\/\/doi.org\/10.1111\/j.1600-079X.2008.00641.x","journal-title":"J Pineal Res"},{"key":"12287_CR68","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/1440-1681.13671","volume":"49","author":"J Osacka","year":"2022","unstructured":"Osacka J, Kiss A, Pirnik Z (2022) Possible involvement of apoptosis in the antipsychotics side effects: A mini-review. Clin Exp Pharmacol Physiol 49:836\u2013847. https:\/\/doi.org\/10.1111\/1440-1681.13671","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"12287_CR69","unstructured":"June N, Brett M, Cowling V (2024) The role of mRNA capping enzyme CMTR1 in hepatocellular carcinoma. and the innate immune response https:\/\/theses.gla.ac.uk\/84921\/"},{"key":"12287_CR70","doi-asserted-by":"publisher","first-page":"869672","DOI":"10.3389\/fonc.2022.869672","volume":"12","author":"M Alam","year":"2022","unstructured":"Alam M, Alam S, Shamsi A, Adnan M, Elasbali AM, Al-Soud WA, Alreshidi M, Hawsawi YM, Tippana A, Pasupuleti VR, Hassan MI (2022) Bax\/Bcl-2 cascade is regulated by the EGFR pathway: therapeutic targeting of non-small cell lung cancer. Front Oncol 12:869672. https:\/\/doi.org\/10.3389\/fonc.2022.869672","journal-title":"Front Oncol"},{"key":"12287_CR71","doi-asserted-by":"publisher","unstructured":"Chen H, Lin Y, Chen J, Luo X, Kan Y, He Y, Zhu R, Jin J, Li D, Wang Y, Han Z (2024) Targeting caspase-8: a new strategy for combating hepatocellular carcinoma. Front Immunol Volume 15:1501659. https:\/\/doi.org\/10.3389\/fimmu.2024.1501659","DOI":"10.3389\/fimmu.2024.1501659"},{"key":"12287_CR72","doi-asserted-by":"publisher","first-page":"104600","DOI":"10.1016\/j.drudis.2026.104600","volume":"31","author":"A Lepailleur","year":"2026","unstructured":"Lepailleur A, Geslin D, Giovannini J, Cuissart B, Lamotte J-L, Bureau R (2026) Mapping ligands for MT1\/MT2 and 5-HT2C receptors: Chemotypes, SAR, and polypharmacology, Drug Discov. Today 31:104600. https:\/\/doi.org\/10.1016\/j.drudis.2026.104600","journal-title":"Today"},{"issue":"2","key":"12287_CR73","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3390\/cancers17020248","volume":"17","author":"M Seres","year":"2025","unstructured":"Seres M, Spacayova K, Sulova Z, Spaldova J, Breier A, Pavlikova L (2025) Dynamic multilevel regulation of EGFR, KRAS, and MYC oncogenes: driving cancer cell proliferation through (Epi) genetic and post-transcriptional\/translational pathways. Cancers 17(2):248. https:\/\/doi.org\/10.3390\/cancers17020248","journal-title":"Cancers"},{"issue":"3","key":"12287_CR74","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.3390\/ijms24032651","volume":"24","author":"T Zubair","year":"2023","unstructured":"Zubair T, Bandyopadhyay D (2023) Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities. Int J Mol Sci 24(3):2651. https:\/\/doi.org\/10.3390\/ijms24032651","journal-title":"Int J Mol Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12287-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12287-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12287-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:17:47Z","timestamp":1784207867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12287-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12287"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12287-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experimental methods were authorized and conducted according to the guidelines of Mutah University Faculty of medicine ethical committee, Jorden, under reference number (33025).","order":2,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1183"}}